SKC podcast

#08 What motivates the World Orphan Drug Congress Europe 2022?

Wed, 2022 / 11 / 30
„Strategy, advocacy and partnering for the orphan drug industry" – this was the slogan of the World Orphan Drug Congress Europe, which was held from November 14th to 17th, 2022.

In our podcast series "Profcast - rare diseases and their therapies", Prof. Matthias P. Schönermark M.D., Ph.D. reports on the three dominant topics incentive systems, harmonization of European HTA processes, and affordability. He also conducts live interviews with Matthias Heck, director of global government affairs at Alexion Pharmaceuticals, and Adam Plich, founder and CEO of Avanzanite Bioscience.

You can find Profcast #08 What motivates the World Orphan Drug Congress Europe 2022? in German language on Spotify and Apple Podcast. Listen in now!

For more information about the World Orphan Drug Congress, visit


About the Profcast

Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.

The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast is published on the last day of a month.

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

Orphan drugs in Germany

Orphan drugs and the specific market access challenges are at the core of our expertise.

EU HTA: European Health Technology Assessment

Achieve planning security: With us you can align your projects and your resource planning comprehensively and at an early stage on the EU HTA and its implications for market access.
to the top